Is BTX a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,062 people get BTX articles and Market Currents by email alert.

Get email alerts on BTX »

HEADLINES:

BioTime CEO Dr. Michael West to Present at USC Minisymposium: Musculoskeletal Development and Repair

Business Wire (Mon, 9:00AM)
BioTime Appoints Franklin Berger to Board of Directors

Business Wire (May 14, 2013)
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.5 Million Grant from Israel’s Office of the Chief Scientist

Business Wire (May 13, 2013)
Position Yourself For Big Returns In The Stem Cell Space: Jason Kolbert
Life Sciences Report • Mon, May 13 • 4 Comments
BioTime Announces First Quarter 2013 Financial Results and Recent Corporate Accomplishments

Business Wire (May 10, 2013)
BioTime and Subsidiary LifeMap Sciences Announce Release of Enhanced LifeMap BioReagents™ Portal Offering Additional PureStem™ Human Progenitor Cells Including Those for Diabetes Research

Business Wire (May 7, 2013)
LifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards® Version 3.10

Business Wire (Apr 30, 2013)
BioTime Announces CFO Succession Plan

Business Wire (Apr 29, 2013)
High But Well-Managed Risk, This Company Is One To Watch Out For
Emerging Equities • Sun, Apr 28 • 10 Comments
BioTime Enters into Worldwide License Agreement with UCLA to Develop Therapy for the Treatment of Stroke

Business Wire (Apr 19, 2013)
LifeMap Sciences Announces Publication of Research Report Describing the MalaCards Database of Human Diseases

Business Wire (Apr 18, 2013)
Companies That Can Mend The Biotech Market: Stephen Brozak
Life Sciences Report • Fri, Apr 12 • 7 Comments
LifeMap Sciences Adds Products Through Partnership with ProSpec-Tany TechnoGene

Business Wire (Apr 10, 2013)
Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy
Bioassociate Consulting • Thu, Mar 28 • 5 Comments
BioTime Announces Fourth Quarter and Fiscal Year End 2012 Financial Results and Recent Corporate Accomplishments

Business Wire (Mar 18, 2013)
The Stem Cell Revolution Can Jump Start Your Portfolio: Jason Kolbert
Life Sciences Report • Fri, Mar 15 • 16 Comments
BioTime to Present at 25th Annual ROTH Conference

Business Wire (Mar 13, 2013)
BioTime Appoints Stephen C. Farrell to Board of Directors

Business Wire (Mar 12, 2013)
BioTime and Romulus Agree to Accelerate Closing Date for Second Tranche of $5 Million Financing

Business Wire (Mar 7, 2013)
BioTime and Subsidiary LifeMap Sciences Announce Data Mining Collaboration

Business Wire (Mar 4, 2013)

To learn more about Seeking Alpha Pro, click here.

High But Well-Managed Risk, This Company Is One To Watch Out For
Emerging Equities • Sun, Apr 28 • 10 Comments
BioTime: Weak Pipeline Unlikely To Deliver
Apsara Biotechnology Research • Mon, Jul 30, 2012 • 1 Comment
BioTime: Backed By Dubious Stock Promoters
Apsara Biotechnology Research • Thu, Apr 26, 2012 • 16 Comments
BioTime: A Track Record Of Broken Promises
Apsara Biotechnology Research • Thu, Apr 19, 2012 • 12 Comments
BioTime Is Running Out Of Time - Short-Sell Idea
Martin Shkreli • Wed, Apr 11, 2012 • 20 Comments
BioTime Inks Progenitor Cell Distribution Deal for China
ChinaBio Today • Sun, Dec 12, 2010

Position Yourself For Big Returns In The Stem Cell Space: Jason Kolbert
Life Sciences Report • Mon, May 13 • 4 Comments
Companies That Can Mend The Biotech Market: Stephen Brozak
Life Sciences Report • Fri, Apr 12 • 7 Comments
Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy
Bioassociate Consulting • Thu, Mar 28 • 5 Comments
The Stem Cell Revolution Can Jump Start Your Portfolio: Jason Kolbert
Life Sciences Report • Fri, Mar 15 • 16 Comments
5 Medical Stock Losers From Last Week With High Short Ratios
Heisenberg Principle • Mon, Feb 11
2 Stem Cell Research Pioneers And Where They Are Today
Craig Keolanui • Mon, Feb 11 • 9 Comments
Geron: Still Standing
Robert Lawton • Fri, Feb 8 • 238 Comments
Insight On Advanced Cell Technology: An Interview With Gary Rabin, Chairman And CEO
Michael J. Ray • Fri, Feb 8 • 26 Comments
Stephen Brozak: Changing The Way Money Is Made And Diseases Are Cured
Life Sciences Report • Fri, Jan 25 • 3 Comments
Stem Cell Technology To Revolutionize The Skin Care Industry?
Charles Moscoe • Tue, Dec 18, 2012 • 5 Comments
4 Cash-Heavy Biotech Stocks That Analysts Rate As Strong Buy
ZetaKap • Tue, Aug 21, 2012 • 1 Comment
6 Biotech Stocks That Could Be In For A Short Squeeze
Joe Springer • Mon, Aug 20, 2012 • 7 Comments
8 Intriguing Small Cap Biotechnology Companies For Your Consideration
Joe Springer • Mon, Aug 20, 2012 • 2 Comments
7 Cash Loaded Healthcare Stocks With Strong Analyst Confidence
ZetaKap • Wed, Jun 20, 2012 • 2 Comments
6 Biotechnology Stocks Flush With Cash, Stamped As Strong Buys
ZetaKap • Thu, Jun 7, 2012 • 1 Comment
5 Cash Hoarding Small Cap Healthcare Stocks With Analyst Love
ZetaKap • Mon, May 28, 2012
Stem Cell Hype Has Yet To Breed Profits
Apsara Biotechnology Research • Tue, May 22, 2012 • 41 Comments
6 Healthcare Stocks With Great Liquidity And Strong Buy Ratings
ZetaKap • Mon, May 7, 2012 • 12 Comments
Stem Cell Biotechs Report 2011 Year In Review: Part II
Chemistfrog • Mon, May 7, 2012 • 1 Comment
China Biotech In Review: Hutchison MediPharma, AstraZeneca Partner On Cancer Drug
ChinaBio Today • Sun, Dec 25, 2011

There are no Transcripts on BTX.

BioTime CEO Dr. Michael West to Present at USC Minisymposium: Musculoskeletal Development and Repair

Business Wire (Mon, 9:00AM)
BioTime Appoints Franklin Berger to Board of Directors

Business Wire (May 14, 2013)
BioTime’s Subsidiary Cell Cure Neurosciences Ltd. Awarded $1.5 Million Grant from Israel’s Office of the Chief Scientist

Business Wire (May 13, 2013)
BioTime Announces First Quarter 2013 Financial Results and Recent Corporate Accomplishments

Business Wire (May 10, 2013)
BioTime and Subsidiary LifeMap Sciences Announce Release of Enhanced LifeMap BioReagents™ Portal Offering Additional PureStem™ Human Progenitor Cells Including Those for Diabetes Research

Business Wire (May 7, 2013)
LifeMap Sciences, a Subsidiary of BioTime, Announces Release of GeneCards® Version 3.10

Business Wire (Apr 30, 2013)
BioTime Announces CFO Succession Plan

Business Wire (Apr 29, 2013)
BioTime Enters into Worldwide License Agreement with UCLA to Develop Therapy for the Treatment of Stroke

Business Wire (Apr 19, 2013)
LifeMap Sciences Announces Publication of Research Report Describing the MalaCards Database of Human Diseases

Business Wire (Apr 18, 2013)
LifeMap Sciences Adds Products Through Partnership with ProSpec-Tany TechnoGene

Business Wire (Apr 10, 2013)
BioTime Announces Fourth Quarter and Fiscal Year End 2012 Financial Results and Recent Corporate Accomplishments

Business Wire (Mar 18, 2013)
BioTime to Present at 25th Annual ROTH Conference

Business Wire (Mar 13, 2013)
BioTime Appoints Stephen C. Farrell to Board of Directors

Business Wire (Mar 12, 2013)
BioTime and Romulus Agree to Accelerate Closing Date for Second Tranche of $5 Million Financing

Business Wire (Mar 7, 2013)
BioTime and Subsidiary LifeMap Sciences Announce Data Mining Collaboration

Business Wire (Mar 4, 2013)
LifeMap Sciences, a Subsidiary of BioTime, Reports Its Databases Currently Utilized by an Estimated Two Million Unique Visitors Annually according to Google Analytics

Business Wire (Feb 11, 2013)
BioTime’s Subsidiary OncoCyte Corporation Provides an Update on the Development of the Novel Pan-Cancer Diagnostic Product PanC-DxTM

Business Wire (Jan 31, 2013)
LifeMap Sciences, a Subsidiary of BioTime, Announces Publication of Research Report Describing Non-Redundant Compendium of Human Non-Coding RNA Authored by GeneCards® Scientists

Business Wire (Jan 30, 2013)
BioTime CEO Dr. Michael West to Present at Scale-Up and Manufacturing of Cell-Based Therapies II Conference

Business Wire (Jan 18, 2013)
BioTime Submits Protocol for Initiation of Human Clinical Trials of Renevia™ in Europe

Business Wire (Jan 10, 2013)

BTX vs. ETF Alternatives

Company Description

Currently, there's no company description for BTX.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, April 19, 9:43 AM BioTime (BTX +4.7%) moves higher after announcing an exclusive licensing agreement with UCLA for the company's HyStem hydrogels which "deliver locally released growth factors to improve recovery from stroke." The company hopes the related research (performed by Dr. Tom Carmichael) will pave the way for an investigational new drug application with the FDA. Comment! [Healthcare, On the Move]
Tuesday, March 19, 12:51 PM BioTime (BTX -7.6%) takes a hit today after reporting late Monday a Q4 loss of $0.12 per share, compared with a loss of $0.11 per share in the same period last year. Revenues were $1.22M, also down from the prior-year quarter. Total revenue decreased by 9% Y/Y, primarily due to lower grant revenue stemming from the completion of it's research grant from the California Institute for Regenerative Medicine, and an overall decrease in the sale of research products. Comment! [Healthcare, Earnings, On the Move]
Tuesday, March 19, 6:48 AM BioTime (BTX): Q4 EPS of -$0.12. Revenue of $1.2M (-30% Y/Y). (PR) Comment! [Earnings, Breaking News, Healthcare]
Thursday, January 10, 4:04 PM BioTime (BTX +4%) finishes the day higher after saying earlier that it's submitted its Clinical Investigation Protocol to European regulators to begin clinical testing of its Renevia stem cell delivery platform. Comment! [Healthcare, On the Move, Global & FX]
Monday, January 7, 1:15 PM Shares of Geron (GERN +2.5%) snd BioTime (BTX +7.6%) both rise today after BTX agrees to buy the intellectual property, including patents and patent applications, and other assets related to GERN's human embryonic stem cell programs. The financial terms of the deal were in a letter of intent announced back in mid-November. Comment! [Healthcare, M&A, On the Move]
Tuesday, December 18, 2012, 9:58 AM BioTime (BTX +1.6%) has developed a method to produce seven distinct types of cartilage, bone, and tendon cells from human embryonic stem cells using the company's PureStem technology. A lab study showed that BioTime's cells, which can be manufactured on an industrial scale, are "progenitors to diverse skeletal tissues of the human body." BioTime expects to file a request for a Phase I trial in Q1. (PR) Comment! [Healthcare]
Friday, November 16, 2012, 8:24 AM Geron (GERN) +7.4% premarket after agreeing to sell its shuttered embryonic stem cell assets to BioTime (BTX), according to a non-binding letter of intent. The deal comes a year after GERN shut down the world's first trial of embryonic stem cells in humans. BTX says it arranged for a $10M investment from an undisclosed private investor to finance the proposed deal. Comment! [Healthcare, M&A, On the Move]
Friday, October 19, 2012, 12:23 PM Geron's (GERN -7.9%) board acknowledges receiving a letter from BioTime (BTX -3.3%) offering to buy its stem cell assets, saying it will review and act in a manner that it believes will be in the best interests of GERN's stockholders. The board adds that it's been considering a number of alternatives since its announcement earlier this month that it was discontinuing its stem cell research and development programs. Comment! [Healthcare, On the Move]
Thursday, October 18, 2012, 9:18 AM Geron (GERN) +5.8% premarket after BioTime (BTX) issues an open letter to GERN shareholders proposing a transaction between the two biopharma companies. Part of the proposal would allow GERN shareholders could own up to 45% of a new publicly traded company that would own GERN stem cell assets. 1 Comment [Healthcare, M&A, On the Move]
Thursday, August 16, 2012, 9:06 AM BioTime (BTX) and its OncoCyte unit publish a paper in which they identify the COL10A1 gene as a potential marker for numerous types of cancer. The upshot for BioTime is that the research should enhance PanC-DxTM, a low-cost device the company's developing to detect cancer using blood samples. (PR) Comment! [Healthcare]
Wednesday, April 11, 2012, 2:59 PM BioTime (BTX -9.3%) shares sink after a Seeking Alpha article by Martin Shkreli says the biotech smallcap is worth ~$20M vs. its current ~$221M market cap. "With only $22M in cash and limited operations... BioTime has a need for raising cash in the future... I predict BTX shares will drop at least 50% in the next 12 months." 2 Comments [Healthcare, On the Move]
Thursday, December 22, 2011, 10:21 AM Shares of BioTime (BTX -5.5%) slip on profit-taking following two-day rally after the firm disclosed (8-K) that it entered into two agreements with China-based USCN Life Science to license technology and patents, as well as purchase assets related to stem cell research. Comment! [On the Move, Healthcare]
Wednesday, December 21, 2011, 10:34 AM BioTime (BTX +4.8%) trades up after signing an agreement with USCN Life Science of Wuhan, China, to license its antibody-producing cell lines and related technology for use in the large-scale manufacture of antibody components for its cancer detection device, PanC-Dx. Comment! [Healthcare, On the Move, Global & FX]
Monday, December 19, 2011, 4:14 PM BioTime (BTX +1%) finishes the day in positive territory after WBB Securities upgraded the stock earlier today to Strong Buy, citing the potential of cancer detection device PanC-Dx. Comment! [Healthcare, On the Move]

Asif Suria
BioTime, Inc. Issues Open Letter to Shareholders of Geron Corporation $GERN $BTX http://bit.ly/Ty8eci
10/18/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
4 Cash-Heavy Biotech Stocks That Analysts Rate As Strong Buy http://bit.ly/NWAqVP $BTX $DYAX $OPTR $SHP @ZetaKap
8/21/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
7 Cash Loaded Healthcare Stocks With Strong Analyst Confidence http://bit.ly/MfGV44 $BGMD $ATRC $CBPO $ANIK $CO $BTX @ZetaKap
6/20/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
6 Biotechnology Stocks Flush With Cash, Stamped As Strong Buys http://bit.ly/NPmZqA $ANIK $BTX $CBPO $IMMU $CRTX $OPTR @ZetaKap
6/7/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
5 Cash Hoarding Small Cap Healthcare Stocks With Analyst Love http://bit.ly/KAioYc $ANIK $CYNO $ATRC $CRTX $BTX @ZetaKap
5/28/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
Analysts Love These 6 Healthcare Picks http://bit.ly/IyMt8v $ATRS $ANIK $ATRC $BGMD $BTX $CRDC
5/7/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

optionsgirl
Genron finally failed, while BTX has been upgraded to BUY.
11/16/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Henry McCusker
Mid-Day Movers: BioTime (AMEX: BTX), Cytori (CYTX), Geron (GERN), Neuralstem (AMEX: CUR), ReNeuron (RENE.LON), ThermoGenesis (KOOL)
10/26/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

candlestickpicks
$BTX completed a Break Out candlestick pattern on 04/24/2011. Look for an upward price movement on 04/25/2011
4/25/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

BTX BioTime, Inc

BTX

BioTime, Inc